Stock Analysis

KORU Medical Systems Full Year 2024 Earnings: In Line With Expectations

NasdaqCM:KRMD
Source: Shutterstock

KORU Medical Systems (NASDAQ:KRMD) Full Year 2024 Results

Key Financial Results

  • Revenue: US$33.6m (up 18% from FY 2023).
  • Net loss: US$6.07m (loss narrowed by 56% from FY 2023).
  • US$0.13 loss per share (improved from US$0.30 loss in FY 2023).
earnings-and-revenue-growth
NasdaqCM:KRMD Earnings and Revenue Growth March 14th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

KORU Medical Systems Earnings Insights

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are down 15% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on KORU Medical Systems' balance sheet health.

Valuation is complex, but we're here to simplify it.

Discover if KORU Medical Systems might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.